- Coordinator
- Oslo Universitetssykehus Hf, Norway
- Runs
- 1 May 2025 to 30 April 2031
- Status
- Running
- EU funding
- €13.6m
- Total cost
- €14.0m
- Partners
- 30 organisations in 16 countries
- Type
- Innovation Action
- Grant agreement
- 101213916
What the project is doing
In the project's own words, from its summary on CORDIS.
We propose an ambitious yet well-conceived and deliverable pan-European, pan-cancer, pan-disciplinary, and multi-omic approach to address the pressing unmet need for an accurate, non-invasive, acceptable and cost-effective method of detecting precancerous and early-stage cancers in those individuals with Lynch syndrome (LS), the most common monogenetic increased hereditary cancer risk. LS has historically been underfunded and underserved, leading to significant an inequality in access and treatment.
As a result, LS carriers have suffered needless cancers and deaths as a result. Our consortium has brought together the leading European experts, biotechnology companies and patient advocates to guarantee deliver practice-changing results that can be rapidly upscaled and adopted across the European Union and globally. Using an innovative clinical trial design, we will evaluate several multiple promising, non-invasive, liquid biopsy-based technologies in the three most common LS cancer types for an early-stage cancers detection.
By leveraging Artificial intelligence (AI), we will identify traces of cancer, ensuring applicability to diverse healthcare systems. A comprehensive framework will assess the broader socio-economic and ethical impacts, ensuring that the solutions align with the societal values and healthcare needs. Parterning with leading biomarker companies (GNT, MSInsight, MSICare, MSIPlus and Elypta), we aim to deliver a multi-omic solution for affordable, accessible and effective test to advance the detection of heritable cancer detections in LS.
This action is part of the Cancer Mission cluster of projects on “Prevention & early detection (early detection heritable cancers).
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Oslo Universitetssykehus Hf | Oslo | Norway | Coordinator |
| European Regional and Local Health Authorities ASBL | Etterbeek | Belgium | Participant |
| Udg Alliance | Lausanne | Switzerland | Associatedpartner |
| Masarykuv Onkologicky Ustav | Brno | Czechia | Participant |
| Eit Health eV | Munchen | Germany | Participant |
| Semi-Colon e.V. | Mönchengladbach | Germany | Participant |
| Predictby Research and Consulting S.l. | Barcelona | Spain | Participant |
| Universidad De Granada | Granada | Spain | Participant |
| Tampereen Korkeakoulusaatio Sr | Tampere | Finland | Participant |
| Institut Curie | Paris | France | Participant |
| Institut Gustave Roussy | Villejuif | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| MSInsight | Paris | France | Participant |
| Protisvalor Mediterranee SAS | Marseille | France | Third party |
| Unicancer | Paris | France | Participant |
| Universite D'aix Marseille | Marseille | France | Participant |
| Klinicki Bolnicki Centar Sestre Milosrdnice Ustanova | Zagreb | Croatia | Participant |
| Fondazione Irccs Istituto Nazionale Dei Tumori | Milan | Italy | Participant |
| Rigas Stradina Universitate | Riga | Latvia | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Universiteit Utrecht | Utrecht | Netherlands | Participant |
| Oslo Cancer Cluster SA | Oslo | Norway | Participant |
| Universitetet I Oslo | Oslo | Norway | Participant |
| Associacao Evita - Cancro Hereditario | Lisboa | Portugal | Participant |
| Europacolon Portugal- Associacao De Luta Contra O Cancro Do Intestino | Porto | Portugal | Participant |
| I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do Porto | Porto | Portugal | Participant |
| Elypta AB | Solna | Sweden | Participant |
| Geneton S.r.o. | Bratislava | Slovakia | Participant |
| The University of Edinburgh | Edinburgh | United Kingdom | Participant |
| University of Newcastle Upon Tyne | Newcastle Upon Tyne | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI